STUDY FINDS BEST-WORST SCALING COMPARABLE TO DISCRETE CHOICE EXPERIMENT IN ESTIMATING PATIENT PREFERENCES

Published Jul 25, 2016
However, Risk Tolerance Thresholds Differ Between the Two Methods Princeton, NJ—July 25, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today the publication of a study comparing the metrics obtained from profile-case best-worst scaling (BWS) with those from a discrete choice experiment (DCE) with respect to hip replacement surgery. The study confirms previous findings that BWS is comparable to DCE in estimating attribute weights and level preferences. However, the risk tolerance threshold based on the estimation of maximum acceptable risk (MAR) differs between these methods, possibly leading to inconsistency in comparing treatment scenarios. The results of this novel research, An Empirical Comparison of Discrete Choice Experiment and Best-Worst Scaling to Estimate Stakeholders’ Risk Tolerance for Hip Replacement Surgery, were published in the June 2016 issue of Value in Health. The authors surveyed the general US population of males aged 45 to 65 years and potentially eligible for hip replacement surgery. The survey included sociodemographic questions, 12 BWS questions, and 8 DCE questions. Attributes were the probability of a first and second revision, pain relief, ability to perform sports and daily activities, and length of hospital stay. Conditional logit analysis was used to estimate attribute weights, level preferences, and the MAR for undergoing revision surgery in six hypothetical treatment scenarios with different attribute levels. The results included data from 429 respondents. “Several research methods can be used to elicit patient preferences,” said corresponding author Catharina G.M. Groothuis-Oudshoorn, PhD, of the Department of Health Technology and Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. “And while discrete choice experiment is the most commonly used stated preference format in health care,” she added, “best-worse scaling has been introduced as an alternative to DCE, and creates the ability to compare the relative impact of attributes.” Dr. Groothuis-Oudshoorn noted that to date, only limited empiric research has been conducted to determine the validity and reliability of both methods with respect to estimating preferences, and previous studies had been inconclusive. Groothuis-Oudshoorn noted that although this research is the first to compare the MAR obtained with either BWS or DCE, “the similar patterns in attribute weights and level preferences when using either BWS or DCE are in agreement with previous studies.” The authors highlight that caution should be taken when using these preferences to calculate a ratio or absolute cut-off value (i.e., the MAR) for decision making. Although it would be easier to have one cut-off value, the results demonstrate that the choice of methodology then could influence the decisions, and the results can thus be sensitive to regulatory decisions. Therefore, it is recommended not to consider only the threshold or absolute value, but to incorporate the underlying respondents’ preferences in the decision making. ###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×